Cite
HARVARD Citation
Pirosa, M. et al. (2022). A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leukemia & lymphoma. 63 (1), pp. 117-123. [Online].